YOLFTbeta
Allarity Therapeutics Inc

Allarity Therapeutics Inc

ALLR · NASDAQ · Healthcare / Biotechnology

0.9538USD+0.04 (+4.38%)

Price History

Full chart

Market Stats

Previous Close0.9138
Open0.93
Day Range0.88 – 0.999
52-Week Range0.7687 – 1.84
Volume279.18K
Market Cap17.34M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.84
Dividend Yield0.00%
Beta0.56
50-Day Avg1.28
200-Day Avg1.24

About

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Thomas H. Jensen
  • Employees7
  • Headquarters123 E. Tarpon Ave., Tarpon Springs, FL, United States, 34689, USA
  • Websitehttps://www.allarity.com

Leadership

  • Mr. Thomas H. JensenFounder, CEO & Director · b. 1978
  • Dr. Jeremy R. Graff Ph.D.President & Chief Development Officer · b. 1970
  • Dr. Steen Meier Knudsen Ph.D.Founder & Chief Scientific Officer · b. 1961
  • Mr. Jeffrey S. Ervin M.B.A.Chief Financial Officer · b. 1978
  • Dr. Jose L. Iglesias M.D.Consultant Chief Medical Officer · b. 1957

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-9.97K362.29K143.28K1.46M1.46M120.00K00000320.00K
Growth (%)--+3532.23%-60.45%+918.31%+0.09%-91.78%-100.00%-----
Cost of Revenue62.94K55.83K--2.22M5.08M-86.00K106.00K120.00K37.00K9.00K-
Gross Profit-62.94K-45.85K362.29K143.28K-761.50K-3.62M120.00K-86.00K-106.00K-120.00K-37.00K-9.00K320.00K
Gross Margin--459.70%100.00%100.00%-52.19%-247.87%100.00%-----100.00%
Operating Expense18.24K22.81K1.76M4.63M3.08M1.36M17.73M8.23M26.45M34.34M17.09M27.23M12.93M
Operating Income-81.19K-68.66K-1.40M-4.49M-3.84M-4.98M-17.61M-8.32M-26.56M-34.46M-17.13M-27.24M-12.61M
Operating Margin--688.39%-385.48%-3132.12%-263.43%-341.19%-14675.83%------3939.06%
EBITDA-0.05-45.85K-1.13M-4.21M-3.83M-4.90M-15.61M-6.01M-25.77M-17.30M-11.28M-24.23M-11.05M
EBITDA Margin--459.71%-312.28%-2937.94%-262.83%-335.42%-13011.67%------3451.87%
Net Income-81.19K-68.66K-1.15M-3.68M-4.90M-2.29M-14.31M-6.60M-26.65M-16.06M-11.90M-24.52M-11.23M
Net Income Margin--688.39%-316.59%-2570.36%-335.69%-156.97%-11927.50%------3509.69%
R&D------6.37M4.22M14.20M6.93M7.10M6.10M6.60M
R&D as % of Total Revenue------5305.83%-----2062.81%
Interest Expense--39.40K43.70K2.42K233.24K3.31M320.00K640.00K223.00K498.00K653.00K185.00K
Interest Expense % of Total Revenue--10.87%30.50%0.17%15.97%2760.00%-----57.81%

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets180.00K93.30K5.45M6.54M2.09M38.59M31.61M33.40M49.63M14.54M11.86M22.65M18.26M
Total Liabilities12.55K14.44K518.15K1.34M1.70M10.69M10.70M6.55M30.85M12.65M14.61M10.84M8.43M
Total Equity167.44K78.87K4.93M5.20M394.04K27.90M20.90M26.85M18.78M1.89M-2.75M11.81M9.83M
Cash50.40K2.07K1.99M2.07M536.03K237.38K1.52M298.00K19.55M2.03M166.00K19.53M14.69M
Total Debt5.54K4.80K---2.90M963.00K1.79M1.09M3.73M1.30M1.35M1.40M
Net Debt-44.86K2.74K-1.99M-2.07M-536.03K2.66M-561.00K1.49M-18.47M1.71M1.13M-18.18M-13.29M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---2.03M-3.98M-1.34M-4.24M-10.11M-7.25M-15.05M-16.82M-12.74M-17.35M-14.82M
Investing Cash Flow--1.67M-178.74K-127.96K1.51M229.00K-3.00K1.00M791.00K--298.00K-8.00K
Financing Cash Flow--3.77M4.31M1.16M2.42M11.20M6.03M33.82M-1.31M10.99M36.79M10.65M
Capital Expenditure00077.84K37.00K5.68K8.00K3.00K18.00K18.00K0298.00K8.00K
Free Cash Flow---2.03M-4.06M-1.34M-4.24M-10.12M-7.25M-15.05M-16.84M-12.74M-17.65M-14.83M
Dividends Paid---------1.51M10.99M--
FCF to OCF--100.00%101.96%100.00%100.13%100.08%100.04%100.00%100.11%100.00%101.72%100.05%
Dividend Paid to FCF----------8.98%-86.27%--

Earnings

Report DateJun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 21, 2021Dec 31, 2021May 27, 2022Aug 22, 2022Nov 14, 2022Mar 13, 2023May 11, 2023Aug 14, 2023Nov 14, 2023Mar 8, 2024May 14, 2024Aug 5, 2024Nov 14, 2024Mar 31, 2025May 9, 2025Aug 15, 2025Nov 14, 2025Dec 31, 2025May 15, 2026Aug 14, 2026Nov 13, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00--554401.11-579601.16-210000.42-0.42-189120.19-6714.01-4902.00-0.25-52.80-8.70-8.40-0.14--0.21-0.23-0.22-0.22-0.25-0.21
EPS Actual-0.02-0.04-0.08-0.08-0.07-0.10-0.17-0.13-0.04-0.05-0.03-0.030.04-0.01-0.05-0.04-0.06-0.05-0.15-0.02-0.00-0.01-0.02-0.01-0.06-0.01-0.12-1000000.00414683.63-436800.87-571201.14-0.23-106320.11-15768.02-1344.00-0.43-664.20-3.30-1.75-1.72-0.25-0.15-0.19-0.21-0.17-0.21-
Surprise----------------------------174.80%24.64%-172.00%45.24%43.78%-134.85%72.58%-72.00%-1157.95%62.07%79.17%-1128.57%-28.57%17.39%4.55%22.73%16.00%-
Timing----------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-market--After-hoursPre-market-After-hoursPre-market-

Key Statistics & Ratios

Market Cap17.34M
Enterprise Value21.69M
Trailing P/E0.00
Forward P/E0.00
Price / Sales50.27
Price / Book4.63
EPS-0.84
Book Value0.222
Revenue (TTM)345.00K
Gross Profit (TTM)345.00K
EBITDA-10.80M
Profit Margin0.00%
Operating Margin-3128.99%
Return on Equity-157.09%
Return on Assets-25.31%
Shares Outstanding15.91M
Shares Float15.86M
Beta0.56
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 11.00
  • Hold
    1

Ownership Breakdown

Institutions
8.05%
Insiders
4.19%
Retail / Other
87.76%

Top Institutional Holders

  • Renaissance Technologies Corp
    228.08K1.43%
  • Geode Capital Management, LLC
    190.39K1.20%
  • Vanguard Capital Management, LLC
    171.79K1.08%
  • State Street Corp
    137.60K0.86%
  • Militia Capital Management, LLC
    98.98K0.62%
  • Citadel Advisors Llc
    91.75K0.58%
  • Vanguard Fiduciary Trust Co
    74.91K0.47%
  • Northern Trust Corp
    48.10K0.30%
  • XTX Topco Ltd
    28.97K0.18%
  • Two Sigma Investments LLC
    27.49K0.17%
  • UBS Group AG
    23.16K0.15%
  • TWO SIGMA SECURITIES, LLC
    12.33K0.08%
  • Citigroup Inc
    7.77K0.05%
  • Capital Advisors, Inc.
    00.00%
  • Bank of America Corp
    00.00%
  • Caitong International Asset Management Co., Limited.
    10.00%
  • Danske Bank A/S.
    10.00%

Top Fund Holders

  • Fidelity Extended Market Index
    82.82K0.52%
  • Fidelity Total Market Index
    22.17K0.14%
  • Fidelity Series Total Market Index
    21.59K0.14%

Stock Splits

  • Sep 11, 20241:30
  • Apr 9, 20241:20
  • Jun 29, 20231:40
  • Mar 27, 20231:35